Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ctce-9908. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 16/20 | 0.68 |
| ▸ | NPY1R | P25929 | 10/20 | 0.68 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.68 |
| ▸ | NPY2R | P49146 | 6/20 | 0.68 |
| ▸ | TFPI | P10646 | 1/20 | 0.63 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.56 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15987269 | 0.94 | NPY4R (0.66) | NPY4RNPY1RNPY5RNPY2RTFPI | |
| SCHEMBL32664689 | 0.86 | NPY4R (0.68) | NPY4RNPY1RNPY5RNPY2RTFPI | |
| SCHEMBL29659761 | 0.84 | TFPI (0.58) | NPY4RNPY1RNPY5RNPY2RTFPI | |
| SCHEMBL29442111 | 0.84 | NPY4R (0.69) | NPY4RNPY1RNPY5RNPY2RTFPI | |
| SCHEMBL30842196 | 0.84 | OPRM1 (0.64) | NPY4RNPY1RNPY5RNPY2RTFPI | |
| SCHEMBL31114989 | 0.84 | TFPI (0.62) | NPY4RNPY1RNPY5RNPY2RTFPI | |
| SCHEMBL29638064 | 0.84 | NPY4R (0.74) | NPY4RNPY1RNPY5RNPY2RTFPI | |
| SCHEMBL31141457 | 0.84 | TFPI (0.70) | NPY4RNPY1RNPY5RNPY2RTFPI | |
| SCHEMBL29993877 | 0.84 | NPY4R (0.65) | NPY4RNPY1RNPY5RNPY2RTFPI | |
| SCHEMBL29901562 | 0.83 | NPY4R (0.69) | NPY4RNPY1RNPY5RNPY2RTFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 289 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724503-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCERS THROUGH INHIBITION OF CELL-IN-CELL PHENOMENON | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4724096-A1 | GPCR INHIBITORS AND USES THEREOF | GPCR Therapeutics, Inc. (KR) | 2026-04-15 | — | — | EP | claimed |
| US-12540165-B2 | HSP fusion protein with anti-chemorepellant agent for treatment of cancer | THE GENERAL HOSPITAL CORPORATION (US) | 2026-02-03 | — | — | US | claimed |
| US-20250381168-A1 | VLA4 INHIBITORS AND USES THEREOF | WASHINGTON UNIVERSITY ST LOUIS (US) | 2025-12-18 | — | — | US | claimed |
| US-20250360149-A1 | GPCR INHIBITORS AND USES THEREOF | GPCR THERAPEUTICS INC (KR) | 2025-11-27 | — | — | US | claimed |
| EP-4536239-A1 | GPCR INHIBITORS AND USES THEREOF | GPCR Therapeutics, Inc. (KR) | 2025-04-16 | — | — | EP | claimed |
| WO-2025059113-A1 | TREATMENTS FOR ENHANCING IMMUNE RESPONSE TO CLOSTRIDIOIDES DIFFICILE INFECTIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2025-03-20 | — | — | WO | claimed |
| WO-2025050038-A2 | GPCR INHIBITORS AND USES THEREOF | GPCR THERAPEUTICS, INC. (KR) | 2025-03-06 | — | — | WO | claimed |
| CN-119562815-A | GPCR inhibitors and uses thereof | GPCR治疗公司 | 2025-03-04 | — | — | CN | claimed |
| WO-2024254584-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCERS THROUGH INHIBITION OF CELL-IN-CELL PHENOMENON | INSTITUTE FOR CANCER RESEARCH d.b.a. THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2024-12-12 | — | — | WO | claimed |
| CN-113975398-B | Drug delivery carrier composition for treating liver fibrosis and preparation method thereof | 中国药科大学 | 2023-07-04 | — | — | CN | claimed |
| CN-116271100-A | Nanometer gel based on immobilized collagenase and preparation method and application thereof | 山东大学 | 2023-06-23 | — | — | CN | claimed |
| US-20230157994-A1 | NEW COMPOSITIONS AND METHODS OF TREATING COVID-19 DISEASE | 4LIVING BIOTECH (FR) | 2023-05-25 | — | — | US | claimed |
| CN-116133657-A | New compositions and methods for treating covd-19 disease | 4活性生物科技公司 | 2023-05-16 | — | — | CN | claimed |
| EP-4146195-A1 | NEW COMPOSITIONS AND METHODS OF TREATING COVID-19 DISEASE | 4Living Biotech (FR) | 2023-03-15 | — | — | EP | claimed |
| US-20220323493-A1 | EX VIVO ANTIGEN-PRESENTING CELLS OR ACTIVATED CD-POSITIVE T CELLS FOR TREATMENT OF CANCER | THE GENERAL HOSPITAL CORPORATION | 2022-10-13 | — | — | US | claimed |
| US-20220275032-A1 | HSP Fusion Protein with Anti-Chemorepellant Agent for Treatment of Cancer | THE GENERAL HOSPITAL CORPORATION | 2022-09-01 | — | — | US | claimed |
| WO-2022140781-A1 | USE OF STROMAL CELL-DERIVED FACTOR 1 (SDF1) AS A BIOMARKER FOR DIAGNOSING AND TREATING SEVERE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) | ANN AND ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO (US) | 2022-06-30 | — | — | WO | claimed |
| US-20220184029-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROBLASTOMA | UNIV CHICAGO (US) | 2022-06-16 | — | — | US | claimed |
| US-11325951-B2 | HSP fusion protein with anti-chemorepellant agent for treatment of cancer | THE GENERAL HOSPITAL CORPORATION (US) | 2022-05-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540165-B2 | HSP fusion protein with anti-chemorepellant agent for treatment of cancer | HSP90AB2P, HSPA2, CDC37 | NPY4R 2453/4885NPY1R 1895/4885NPY5R 2457/4885 |
| US-20250381168-A1 | VLA4 INHIBITORS AND USES THEREOF | CXCR4, SDF4, ITGB4 | NPY4R 2630/4885NPY1R 4719/4885NPY5R 4775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.